← SynDRA
PKI-166
SynDRA canonical compound SYN0028809 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | EGFR | ERBB2 |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- EGFR MODULATOR
Drug classes
- Protein Kinase Inhibitors
Cross-references
Synonyms
- CGP-75166
- NVP-PKI166
- PKI166
- CHEMBL1914653
- AC1OCFE0
- UNII-9RIE5HW38P
- 9RIE5HW38P
- SCHEMBL177814
- GTPL7642
- CHEMBL1963502
- ZINC23255
- AOB1619
- PKI-75166
- BDBM50358046
- NCGC00387215-02
- AS-16676
- KB-275097
- PKI-166, >
- 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol
- CGP 75166
- CGP75166
- RefChem:174653
- SCHEMBL185822
- orb1706783
- PKI 166 [WHO-DD]
- SCHEMBL29352405
- GLXC-02528
- MHA72461
- EX-A10718
- MFCD09970842
- AKOS037643509
- AC-37957
- DA-76941
- HY-117155
- PKI-166, >=98% (HPLC)
- CS-0064017
- G13676
- T16549
Look up PKI-166 in the interactive SynDRA portal →